Digital Therapeutics: An Adoption Framework
Digital therapeutics adoption depends on more than a working application. Buyers need a clear intended use, evidence matched to the population, a route into care, accountable clinical ownership, patient support, and a sustainable operating model.
What is the adoption decision?
Define whether the organisation is assessing a therapeutic intervention, a companion to an existing service, a monitoring tool, or a behaviour-support product. The intended use sets the evidence, oversight, workflow, and access questions. A patient-facing application cannot be evaluated only as a software purchase when it influences care decisions or adherence.
Name the user and the point of responsibility. Is the product prescribed, recommended, reimbursed, offered by an employer, or used directly by a patient? **Adoption becomes clearer when the route from eligibility to ongoing support is visible.**
How should clinical and user evidence be read?
Ask which population was studied, which comparator was used, how long the intervention ran, what outcomes were measured, and what support users received. Separate engagement from clinical benefit. A user opening an application is not the same as a patient achieving a meaningful outcome.
Review usability, accessibility, language, device requirements, data handling, and the reasons people stop using the product. The [WHO digital health guidance](https://www.who.int/health-topics/digital-health) is a useful source for understanding how digital health evidence and deployment questions can be structured. Product-specific diligence remains necessary.
What workflow must be designed around the product?
Map referral or prescription, onboarding, consent, activation, reminders, support, escalation, review, and completion. Decide who sees the data, who responds to a concerning signal, and when the patient should contact a clinician. A product without a response path can add responsibility without adding care capacity.
Pilot with the people who will run the workflow, not only with enthusiastic early users. Test missed sessions, device changes, low digital confidence, language needs, clinical escalation, and withdrawal. **The care team must know what the product can and cannot tell them.**
How do access and commercial fit affect the market?
Assess who pays, who authorises, who prescribes or recommends, and who supports the patient. Include procurement, reimbursement or funding evidence, eligibility rules, patient support, and the administrative burden. A clinically useful product can still fail to scale if access requires a process no team can sustain.
Model the total pathway rather than the licence alone. Include implementation, training, integration, patient support, clinical review, reporting, and renewal. **A durable model makes the value visible to every participant in the pathway.**
What governance should be in place?
Review clinical ownership, data protection, safety reporting, content changes, version control, cybersecurity, accessibility, and incident response. Set criteria for pausing or changing the product. The governance model should explain how patient feedback, clinician feedback, and outcome data change the service.
Keep claims tied to evidence and intended use. A marketing statement can travel farther than the study that supports it. Use plain language about limitations and distinguish an outcome supported by evidence from a future possibility.
Options compared
Adoption options range from a narrow service pilot to a broad platform or a partnership with an existing care pathway. Choose based on evidence, ownership, access, and support capacity.
A smaller, bounded launch can reveal the workflow and support burden before an organisation commits to a wider population.
| Adoption route | Best fit | Main question | Common risk |
|---|---|---|---|
| Care pathway pilot | Defined clinical population | Can the team run it safely? | Support burden |
| Payer or employer programme | Population-level access | Is value visible to the sponsor? | Eligibility and engagement |
| Direct patient offer | Self-directed use | Can users understand and sustain it? | Limited clinical oversight |
| Platform partnership | Several programmes | Can governance scale? | Integration and accountability |
What does not matter as much as buyers think
A modern interface, a large feature list, and high early engagement do not establish clinical or commercial value. **The decisive signals are appropriate evidence, safe workflow integration, patient support, access, and accountable ownership.**
Do not treat the app as the whole intervention. The market offer includes onboarding, human support, data review, escalation, and the operating rules around the software.
Buyer checklist
- Define the digital therapeutics: an adoption framework decision in terms of the users, scope, timing, and owner who will act on the result.
- List the inputs, dependencies, boundaries, and exclusions that shape this healthcare & life sciences question before comparing suppliers or methods.
- Separate observed evidence, supplier claims, assumptions, and judgement so the final recommendation remains traceable.
- Test the normal path, a missing input, an exception, an outage, and a change in ownership before calling the option ready.
- Model implementation, support, governance, monitoring, training, renewal, and exit instead of comparing only the purchase price.
- Set a baseline, success criteria, review date, and stop or scale condition that the operating team can measure.
- Record what would change the decision, which evidence is still missing, and who owns the next review.
Use this checklist as a working brief for the digital therapeutics: an adoption framework decision. Keep the evidence, assumptions, and open questions together so a later review can update the conclusion without rebuilding the entire case.
Questions to take into a review
- Which user, customer, or operator is this digital therapeutics: an adoption framework decision meant to help?
- What evidence supports the proposed result, and what evidence is still a claim or assumption?
- What happens when the input is incomplete, delayed, wrong, or unavailable?
- Which team owns the workflow after implementation, including support, monitoring, and exception handling?
- What dependencies, permissions, integrations, or changes could delay adoption?
- How will the organisation measure value, risk, cost, and unintended work after launch?
- What is the smallest reversible test that could strengthen or reject the decision?
For a digital therapeutics: an adoption framework review, keep the decision boundary explicit. If the evidence answers a narrower question than the team wants to decide, say so. A useful next step may be more data, a smaller pilot, a different supplier, or a decision to wait. That clarity is part of the research value. It also makes the final recommendation easier to explain to finance, operations, risk, and leadership teams. Do not hide uncertainty in a footnote. Keep the working record with the final answer so future reviewers can see how the conclusion was formed. That is how a useful article becomes a disciplined decision brief for review. It keeps the scope honest when several teams have different expectations about what the evidence can prove. That discipline prevents a technical benchmark from being mistaken for a complete business case. It also gives the buyer a clean record for procurement, implementation, and later renewal decisions. That record should be brief enough to use, and detailed enough for teams to audit and revisit in a later review.
FAQ
What should a digital therapeutics buyer define first?
The intended use, population, outcome, user, route into care, support model, and accountable owner.
Is engagement proof of therapeutic value?
No. Engagement is one signal. Buyers also need evidence of relevant outcomes, safety, usability, and workflow fit.
Who supports a patient after onboarding?
That responsibility must be explicit before launch, including escalation, missed use, technical issues, and clinical concerns.
How should access be assessed?
Map who pays, authorises, prescribes or recommends, supports, and reviews the product across the full pathway.
Where can I read adjacent market context?
Start with the [healthcare category](/categories/healthcare/) and the [digital health report](/reports/global-digital-health-market/).
Sources and further reading
Browse the research categories, read a related report, or talk to an analyst about a focused brief.